Newsroom | 5168 results

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE : HIMS), la principale plateforme de santé et de bien-être, annonce aujourd'hui la disponibilité du sémaglutide générique par l'entremise de sa plateforme pour les clients admissibles au Canada. Cela rend le traitement GLP-1 abordable et accessible aux Canadiens pour qui le coût a longtemps été un obstacle au traitement. Pour les clients éligibles, des plans de traitement personnalisés sont disponibles à partir de 149 CAD/mois. Les tr...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, will present new findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where the cancer center will showcase 49 abstracts spanning solid tumors and blood cancers. This year’s research, to be prese...

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for p...

TORONTO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at $149/month CAD. GLP-1 treatments have transformed obesity and metabolic health, with...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key Facts The sNDA was supported by the Phase III FINE-ONE trial, which showed KERENDIA significantly reduced urine albumin-to-creatinine rati...

ATLANTA--(BUSINESS WIRE)--City of Hope® Cancer Center Atlanta, part of one of the largest and most advanced cancer research and treatment organizations in the United States, has achieved internationally recognized accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). FACT accreditation is awarded to programs that meet the most rigorous standards across every aspect of cellular therapy, from patient care and donor management to cell collection, processing, and adminis...

LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva Bio” or “the Company”), a clinical-stage biotechnology company advancing a scalable, once-weekly oral obesity product pipeline, today announced that two abstracts have been selected for poster presentations at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana. The presentations include new preclinical data for VRB-103, a once-weekly oral amylin receptor-s...

LONDON & ROME--(BUSINESS WIRE)--Keyron today announced publication in Gut, the highest-ranked gastroenterology journal globally (Impact Factor: 26.2), demonstrating that its ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomized preclinical study. Widely regarded as the most metabolically effective and invasive bariatric...

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten...

NEW YORK--(BUSINESS WIRE)--HITLAB, the independent healthcare innovation and research laboratory affiliated with Columbia University, today released its Summary of Evidence Paper on MedsEngine®. HITLAB was engaged to conduct an independent, structured evaluation of the MedsEngine platform and its supporting clinical evidence base. The evaluation, completed in March 2026, encompassed a full walkthrough of all four disease modules, clinical workflow integration assessment, usability analysis usin...